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STUDY PROTOCOL

TRIALS
Open Access

Analgesic effect of cathodal transcranial
current stimulation over right dorsolateral
prefrontal cortex in subjects with muscular
temporomandibular disorders: study
protocol for a randomized controlled trial
Rivail Almeida Brandão Filho1,2, Abrahão Fontes Baptista3, Renata de Assis Fonseca Santos Brandão1,2,
Francisco Monteiro Meneses3, Jeffrey Okeson4 and Eduardo Pondé de Sena5*

Abstract
Background: Temporomandibular disorders are a group of orofacial pain conditions that are commonly identified
in the general population. Like many other chronic pain conditions, they can be associated with anxiety/
depression, which can be related to changes in the activity of the dorsolateral prefrontal cortex. Some studies have
demonstrated clinical improvement in subjects with chronic pain who are given therapeutic neuromodulation.
Transcranial direct current stimulation is a noninvasive brain stimulation technique that allows the modulation of
neuronal membranes. This therapy can enhance or inhibit action potential generation in cortical neurons. In some
instances, medications acting in the central nervous system may be helpful despite their adverse side effects. It is
important to determine if cathodal transcranial direct current stimulation over the dorsolateral prefrontal cortex, an
area that modulates emotion and motor cortex excitability, has an analgesic effect on chronic temporomandibular
disorders pain.
Method/design: The investigators will run a randomized, controlled crossover double blind study with 15 chronic
muscular temporomandibular disorder subjects. Each subject will undergo active (1 mA and 2 mA) and sham
transcranial direct current stimulation. Inclusion criteria will be determined by the Research Diagnostic Criteria for
Temporomandibular Disorders questionnaire, with subjects who have a pain visual analogic scale score of greater
than 4/10 and whose pain has been present for the previous 6 months, and with a State-Trait Anxiety Inventory
score of more than 42. The influence of transcranial direct current stimulation will be assessed through a visual
analogic scale, quantitative sensory testing, quantitative electroencephalogram, and the State-Trait Anxiety
Inventory score.
(Continued on next page)
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(Continued from previous page)

Discussion: Some studies have demonstrated a strong association between anxiety/depression and chronic
pain, where one may be the cause of the other. This is especially true in chronic temporomandibular disorders,
and breaking this cycle may have an effect over the symptoms and associated dysfunction. We believe that by
inhibiting activity of the dorsolateral prefrontal cortex though cathodal transcranial direct current stimulation,
there may be a change in both anxiety/depression and pain level. Transcranial direct current stimulation may
emerge as a new tool to be considered for managing these patients. We envision that the information obtained
from this study will provide a better understanding of the management of chronic temporomandibular
disorders.
Trial registration: This trial was registered at clinicaltrials.gov on 24 May 2014 (Identifier: NCT02152267).
Keywords: Anxiety, Chronic pain, Temporomandibular, Musculoskeletal diseases, Electrical stimulation, Brain
prefrontal cortex

Background
Pain is among the most common complaints reported by
patients seeking care in a hospital setting or in a primary
care unit. Patients with pain due to temporomandibular
disorders (TMD), which are musculoskeletal disorders of
the masticatory structures, are very common in the general
population. Temporomandibular and craniofacial disorders
are so prevalent that the International Headache Society
has developed a classification for the many different types
of head pain. The third edition of the International Classification of Headache Disorders was published in 2013 [1].
There are several strategies used to manage patients
with TMD. Since there are many types of TMD, it is
critical that clinicians make the proper diagnosis so that
appropriate treatment is selected. Treatment strategies
range from patient education and self-management to
dental procedures and surgery. The most common
symptom associated with TMD is muscle pain, which is
often managed by cognitive awareness, behavioral changes,
and stress management [2].
A study using functional brain imaging showed that,
although the majority of temporomandibular disorders
are associated with muscle pain, as they become chronic
they are likely to have a centralnervous system (CNS)
component [3]. Supporting this concept are behavioral
studies that have demonstrated that TMD is often associated with psychopathology [4, 5].
It is now commonly accepted that chronic pain involves
significant modifications in central neuronal excitability.
In a fibromyalgia study using transcranial magnetic stimulation (TMS), the authors found higher thresholds in both
sides of the resting motor cortex with lower up regulation
responses. Furthermore, they found lower intracortical facilitation and inhibition. The effects of neural modulation
to manage chronic pain are presently being studied [6].
Transcranial direct current stimulation (tDCS) modulates neuronal membranes of cortical neurons, enhancing
or inhibiting their action potentials. Experimental animal
studies have shown that anodal stimulation depolarizes the

nerve membrane, which results in a long-term potentiation
in the stimulated area [7, 8]. Some studies have shown pain
reduction in subjects with fibromyalgia and chronic pain
using neuromodulation [9–13]. Some suggest that anodal
stimulation over the motor cortex decreases pain intensity
by modulating the activity in the neuronal networks responsible for pain. Another study that evaluated the role of
the thalamic ventral caudal nucleus in nociception, suggested a decrease of thalamic pain control output capacity
in chronic pain patients [14]. Transcranial direct current
stimulation may facilitate the descending inhibition of pain;
however, the current evidence is weak [15].
Others studied the effects when transcranial direct
current stimulation (tDCS) is placed over the dorsolateral
prefrontal cortex (DLPFC) [16]. This area is involved with
anxiety and depression without direct analgesic effect. Although not the objective, the authors found anxiety modulation after tDCS application over the DLPFC, when the
cathode was placed over the right side (F4) and the anode
on the left side (F3). These results show weak evidence of
tDCS effects on anxiety, but they do suggest the need for
additional investigation [16]. The modulation of DLPFC
may also have analgesic effects through its excitatory interaction with the primary motor cortex [17].
If cathodaltDCS over the DLPFC has an analgesic effect through modulation of negative emotions, another
important issue is to determine the best stimulation intensity to achieve this goal. Previous tDCS studies have
used 1 or 2 mA, with 2 mA being more common. There
is discussion regarding which intensity is more appropriate with cathodal tDCS. Some authors found that either
2 mA cathodal or anodal stimulation led to increased excitability of the primary motor cortex, whereas 1 mA
stimulation had a specific effect, with cathodal current
decreasing cortical excitability [18].
An advantage of tDCS is that it has minimal side effects.
The most common adverse effects are itching, tingling,
and mild headache that resolve just after the stimuli is terminated. These adverse effects depend on the intensity and
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duration of the treatment session. The most common protocols use a lower intensity (1 or 2 mA) with a treatment
session duration of 20 or 30 minutes. To access tolerability
and safety of tDCS, a side effect questionnaire has been developed [19].
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Intervention groups

Each subject will be tested to determine the effect of
cathodal tDCS over the DLPFC on anxiety using two different currents, 1 mA and 2 mA.
Intervention A

Aims
The main objective of this study is to investigate whether
cathodal tDCS over the right DLPFC has analgesic effects
in subjects with muscular TMD pain. This study will: (1)
evaluate the tDCS effect on pain perception and pressure
threshold; (2) evaluate whether tDCS has any effect on
modifying anxiety and stress; (3) evaluate whether an
EEG’s waves change from pre- to post-tDCS; (4) investigate whether there is an association of pain intensity with
anxiety and EEG data pre- and post-tDCS; (5) compare
the effects of 1 mA and 2 mA over pain intensity, anxiety,
stress, and EEG.
Methods
Study design

This is a randomized, controlled crossover double blind
study with one group undergoing three different interventions. Treatment order will be determined randomly.
The CONSORT guidelines from 2010 to clinical trials
will be used to guide the procedures [20].
Eligibility criteria

To be included in this study, subjects must: (1) provide informed consent to participate in the study; (2) be between
18–60 years old, regardless of gender; (3) have a diagnosis
of muscular TMD pain according to IA and IB, Axis I of
Research Diagnostic Criteria for Temporomandibular
Disorders (RDC/TMD); (4) have a visual analog scale
(VAS) pain score of 4 or greater, present regularly for
6 months or longer; (5) have a State-Trait Anxiety Inventory (STAI) score of more than 42.
Subjects will be excluded from this study if they (1)
are pregnant; (2) have contraindications to tDCS, such
as metal implants on the head or implanted brain devices; (3) have a history of alcohol or drug abuse within
the past 6 months as self-reported; (4) have used carbamazepine within the past 6 months as self-reported; (5)
have a history of epilepsy, stroke, moderate-to-severe
traumatic brain injury, or severe migraines; (6) have a
history of neurosurgery as self-reported; (7) have a history of temporomandibular joint problems such as disc
displacement, arthralgia, osteoarthritis, or osteoarthrosis (Axes I, II, and III diagnosis from RDC/TMD); (8)
have a major psychiatric disorder such as schizophrenia
or bipolar disorder; (9) have had any other previously
diagnosed disorder that has pain symptoms similar to
muscle TMD, such as fibromyalgia.

This intervention will involve 1 mA tDCS, cathodal over
the right DLPFC (F4). The anode will be placed over the
contralateral supraorbital area (Fp1). Stimulation will be
applied over a 20-minute period.
Intervention B

This intervention will use the same parameters as intervention A, but using 2 mA.
Intervention C

This will be the sham intervention. Stimulation electrodes will be placed at the same areas as for interventions A and B, but the current will be applied only for
the first 30 seconds, after which it will be reduced gradually until it reaches zero. This method has been shown
to be effective in previous studies [21].
In all the intervention groups, tDCS will be applied using
35 cm2 (5×7 cm) sponge electrodes soaked in saline solution (140mMolNaCl, water dissolved in Mille-Q). Anodal
and cathodal electrodes will be connected in the tDCSdevice (Soterix Medical 1 × 1 tDCS 1300A, USA). Two 9-V
batteries will deliver current.
All subjects will receive only one stimulation session for
each type of intervention (IA, IB and IC), for a total of
three sessions. After each tDCS session, the subject will
complete a questionnaire to record any adverse affects. A
trained researcher (RABF) will perform each procedure.
One researcher who is responsible for the general supervision (EPS) during testing will hold the randomization list,
and only the clinician responsible for the tDCS stimulation will know which intervention group is being applied.
All clinical and neurological assessments will be performed at the Functional Electrostimulation Laboratory at
Federal University of Bahia (Salvador, Brazil).
As this is a crossover study with only four weekly sessions, we believe that there will not be a compliance
problem. Furthermore, since side effects are minimal,
there is a low risk of dropouts due to this reason.
Control group

As a crossover study, each subject will be his/her own
control. This choice is supported by studies that evaluated motor cortical excitability with transcranial magnetic stimulation (TMS) and found that a single tDCS
session is able to modify cortical excitability for up to
1.5 hours after the end of stimulation. This suggests that
a carryover effect is not an issue [22, 23]. Furthermore,
EEG data is one of our outcome measures, and individual
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characteristics are crucial in this analysis [24], being minimized by a crossover design.
Outcomes

The primary outcome of this study will be the extent to
which this method will change baseline pain intensity
(VAS). The subjects will record their experience on a
daily basis in a pain diary. A weekly response average
will be calculated before the first intervention and after
each session. The averages will be used to compare the
VAS values before and after each intervention. A decrease
of 50 % will be considered a satisfactory clinical
improvement.
Secondary outcomes will be the degree of change from
baseline in power density of alpha and theta EEG bands.
Other outcome measures will be pain pressure threshold
(PPT), mechanical pain thresholds (MPTs), and STAI.
Increase in PPT and mechanical thresholds indicate an
improvement in subject pain condition; a decrease in
STAI indicates a better emotional state.
Participant timeline

All study procedures are depicted in Fig. 1, and the visit
summary is given in Table 1.

Fig. 1 Flow of study procedures
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Sample size

Following IMMPACT (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trial) [25] recommendations for clinical trials involving chronic pain,
we considered our primary outcome measure to be pain
intensity changes, assessed through a VAS. We achieved
a sample size of 15 subjects (G*Power 3.1), considering a
reduction of 50 % (effect size of 0.5), a study power of
80 %, an alpha value of 5 % (P < 0.05), and six measures
(three pre- and post-measures) on three intervention
groups (placebo, and tDCS 1 mA and 2 mA).
Recruitment

The subjects will be identified from the database of a public dental reference center (COAT – Faculty of Dentistry,
Federal University of Bahia, Brazil).
Allocation of interventions

Subjects will be consecutively randomized in order of
the interventions using the tool from randomization.com
(DallalGE, http://www.randomization.com). This study
will use the second generation suggested for crossover
studies. Only the investigators assigned to apply tDCS
will have access to the randomized list. This list will be
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Table 1 Visit summary
V1

V2

V3

V4

Baseline/
consent

1st
session

2nd
session

3rd
session

Consent form

X

RDC/TMD

X

VAS pain diary

X

All subjects will be treated during a single session for
three different interventions (IA, IB,or IC) with a washout period of 7 days between treatments in order to
avoid any residual effects. As reported earlier, a single
tDCS session usually is able to modify cortical excitability for 1 hour after stimulation [22, 23].

X

X

X

VAS pain (pre-tDCS)

X

X

X

Procedure details

Sensory testing
(pre-tDCS)

X

X

X

EEG recording
(pre-tDCS)

X

X

X

tDCS stimulation
(IA, IB, or IC)

X

X

X

Adverse effects
questionnaire

X

X

X

Recently, a new version of RDC/TMD, now called Diagnostic Criteria for Temporomandibular Disorders (DC/TMD),
was published [26]. However, since the new DC/TMD was
not translated and validated into Brazilian Portuguese, we
have decided to use the already-validated Brazilian version
from 2004 [27]. This instrument will only be used to determine inclusion criteria.
RDC/TMD evaluation has two axes, one for assessing
clinical characteristics (Axis I), and the other for assessing the psychosocial aspects (Axis II). As the specific
instrument used to assess anxiety and depression will be
the STAI scale, only Axis I of RDC/TMD will be used.
The RDC/TMD has three diagnostic groups: (1) muscle
disorders; (2) disc displacements; (3) arthralgia/arthritis/
arthrosis [28]. Subjects who present only with muscle
disorders will be included.

VAS pain (post-tDCS)

X

X

X

X

X

X

EEG recording
(post-tDCS)

X

X

X

Sensory testing
(post-tDCS)

X

X

X

3 hours

3 hours

3 hours

ISTA

Approx. time

X

1 hour

opened only when all data are available and analyzed,
unless a subject has a side effect that justifies the interruption of the procedure.
Data collection procedure

After COAT institutional authorization, subjects will be
contacted by phone to ascertain their interest. All interested participants will complete a pre-screening questionnaire. Each subject will be scheduled for an appointment
in order to further determine if they meet the inclusion
criteria. If they do, they will sign an informed consent and
be formerly enrolled in the study.
Women of childbearing age will be required to take a
urine pregnancy test during the screening process. If a
subject becomes pregnant during the course of the
study, she will be withdrawn. During this initial appointment, the subject will be asked to complete a daily pain
VAS diary for 7 days. The average VAS score from this
data will be used as a baseline pain value.
During a second visit (T2) all clinical and neurological
assessments will be performed before and after the tDCS
stimulation. The clinical assessments will be measured
by VAS pain scores, anxiety measures, and quantitative
sensory tests. Neurophysiological assessment will be
measured by using an EEG to analyze cortical activity.
Each patient will be clinically and neurologically assessed
before and after the treatment session resulting in six
data collection points (T2 to T7).

Visual analog scale (VAS) for pain

The VAS allows us to convert subjective sensations, such
as pain, into numerical data. A 10-cm scale, where 0 cm
is no pain and 10 cm is the worst imaginable pain, will
be used, and the subjects will be asked to mark a point
on the scale representing their pain intensity. This instrument will be completed everyday in the 7-day period
after their acceptance. An average pain intensity score
will be calculated as a baseline for the first treatment
intervention. Averages for each week will be used to
analyze if there will be any treatment carryover effect.
The VAS scores will be recorded before and after each
treatment session to verify treatment effect.
State-Trait Anxiety Inventory (STAI)

The STAI is used to evaluate objectively both aspects of
anxiety: trait and state. Analyzing trait will show the personality, auto image, and the way that the subject realizes
and perceives threatening situations. State anxiety is a
transitory emotional state, in response to environmental
stimuli such as tachycardia, sweating, nausea, and cramps.
The questionnaire addresses 20 possible sensations for
each. We will analyze values from 1 to 4, where 1 is never,
2 sometimes, 3 often, and 4 always. The results reveal
whether the subject tends to present low levels of anxiety
(20–40 points), middle levels of anxiety (41–60 points), or
high levels of anxiety (61–80 points).
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Quantitative sensory testing

Mechanical perception and pain threshold will be
tested using Semmes-Weinstein monofilaments (0.008
to 300 g/mm2). Monofilament application will be at a
masseter tender point with the control being the
contralateral thenar area (the palm of the hand at the
base of the thumb). Hairs will be applied gradually,
until the subject perceives the stimulus (sensory perception threshold). The intensity will be increased until
the subject describes it as painful (pain threshold). The
thresholds will be taken at the lowest force that causes
sensory/pain perception. The side of the most painful
masseter will be used for both assessments.
Pain pressure threshold (PPT)

PPT will be determined by applying blunt pressure by a
hard-rubber probe, using an approved device (EMG
1630WF, EMG System, Brazil). During the test, pressure
will be applied to the same area as in the mechanical
perception and pain threshold tests, with increasing intensity at a rate of 1 kg/second. When the subject reports that he/she feels any pain, the procedure will be
stopped. A computer program (EMGLab, EMG System,
Brazil) will automatically record the value. This procedure will be repeated three times to achieve an average.
These tests will take approximately 7–10 minutes to
be completed.
Electroencephalogram (EEG)

The EEG is a powerful tool to assess changes related to
anxiety [29]. It will measure the brain’s electrical current
intensity, using the analysis of alpha and theta waves.
Alpha waves are related to physical relaxation and are
higher when the subject keeps his/her eyes closed. Alpha
power density is reduced when the eyes are open. The
same can be seen in relaxation and alertness respectively. Theta waves are related to awareness states and
are higher chronic pain conditions.
For this study, a 32-channel EEG (BrainNet BNT 36,
EMSA, Brazil) will be used. Data will be band pass filtered
(0.5 to 50 Hz) and acquired at 200 Hz. The channel location will be used according to the International 10–20 EEG
System. Wave power and frequency will be checked before
and after tDCS stimulation. The reference electrodes will
be located at Cz. The data will be analyzed in MATLAB
(The Mathworks, Inc., Natick, MA, USA). After signal filtering, data will be epoched into 1.28-second segments to
standardize artifact removal. Artifacts will be removed
using EEGLab (the semi-automated rejection EEGLab).
Epochs containing extreme values (above −750 and below
750 μV) will be rejected using independent component
analysis (ICA), removing the first component. After artifact
removal, a frequency analysis will be run based on
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the following band widths: a) theta (4–8 Hz), b)
alpha (8–12 Hz), and c) beta (13–30Hz).
Safety monitoring

At each stimulation session, subjects will complete a
questionnaire to evaluate potential adverse effects of
tDCS (tingling, burning sensation, headache, neck pain,
mood alterations) on a 5-point scale. Subjects will be
asked whether they experienced any side effects in an
open-ended manner, and they will be specifically asked
about headache, neck pain, scalp pain, burning sensations, tingling, skin redness, sleepiness, trouble concentrating, and acute mood change.
Study variables

The dependent variables will be (1) VAS for pain intensity, (2) STAI, (3) quantitative sensory testing, and (4)
EEG quantitative analysis. The independent variables
will be (1) cathodal tDCS over DLPFC (1 mA and 2 mA)
and (2) sham treatment.
Statistical methods

The data will be recorded and analyzed by a blinded biostatistician. First, a descriptive analysis of variables will
be performed. Data distribution will be analyzed using
the Shapiro-Wilk test. To check carryover effects between sessions, we will carry out a t-test or a Wilcoxon
rank sum, depending on the normal distribution.
Outcome measures will be compared both between and
within groups considering pre- and post-interventions with
repeated measures analysis of variance or nonparametric
correspondence tests (Friedmann and Mann–Whitney
tests). Clinical data will be correlated to EEG data through
correlation tests (Spearman or Pearson). Significance will
be established at an alpha value of 5 %, with a study power
of 80 %. All data will be analyzed with intention-to-treat.
Ethical aspects

This protocol will be performed in accordance with
resolution 466/2012 of the Brazilian National Research
Ethics Committee (CONEP – ConselhoNacional de
Éticaem Pesquisa). The Ethics Committee of Maternidade Climério de Oliveira, Federal University of Bahia
approved this protocol (process number: 659.0460).
Ten sessions of the best treatment protocol found in
this study will be offered to all the participants at the
end of the analysis.
Technical and scientific resources

The two important goals of this research are to establish
the most effective protocol for tDCS and to demonstrate
a therapy that may be useful for TMD patients. The use of
tDCS for TMD is feasible in clinical practices that have
many patients presenting with this disorder. tDCS is
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noninvasive, low cost, and easy and rapid to implement.
Further, this treatment has minimal adverse effects.

Discussion
Most strategies for treating TMD are aimed directly at
the craniofacial muscles, applying physiotherapy on the
temporomandibular joint (TMJ) and/or on the jaws and
on the occlusion of teeth [2]. Since chronic TMD is
likely to have a central nervous system component in its
etiology, some drugs, such as tricyclic antidepressants,
may have a positive effect on TMD symptoms. However,
after long-term use, some patients become resistant to
the effects of these medications, resulting in the return
of pain. In addition, some of these medications have undesirable side effects [30].
Based on past studies that have demonstrated changes
in brain activity in chronic pain patients [6, 11], it is
promising that this treatment may be helpful in chronic
TMD. If this is true, tDCS may emerge as an adjunctive
therapeutic tool that can be coupled with other effective
treatments already in use.
There seems to be a correlation between anxiety and
muscular hyperactivity [5], yet there is no evidence that
tDCS placed over the emotional areas of the brain decreases anxiety [16]. This study may help shed light on
whether tDCS over the DLPFC has an analgesic effect
when stimulating the emotional areas and if different
amplitudes result in different effects. Perhaps neuromodulation by tDCS over the DLPFC may decrease anxiety
and consequently muscular hyperactivity. This may also
lead to a reduction of chronic TMD pain.
The tDCS technique has shown promising results for
the treatment of chronic pain associated with several
types of disorders [9, 13, 31]. We are hopeful that tDCS
may be effective for the management of painful TMD.
Trial status
We are recruiting subjects.
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